<DOC>
	<DOCNO>NCT00785785</DOCNO>
	<brief_summary>This study evaluate efficacy safety nilotinib versus imatinib adult patient unresectable metastatic gastrointestinal stromal tumor ( GIST ) .</brief_summary>
	<brief_title>A Study Nilotinib Versus Imatinib GIST Patients</brief_title>
	<detailed_description />
	<mesh_term>Gastrointestinal Stromal Tumors</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>1 . Histologically confirm diagnosis GIST unresectable and/or metastatic either : receive prior antineoplastic therapy adjuvant imatinib . Note : newly diagnose patient may receive 14 day treatment imatinib disease management await entry study recurrent GIST stop adjuvant treatment imatinib subsequent treatment therapy . 2 . At least one measurable site disease CT/MRI scan 3 . Performance status â‰¤ 2 ( capable selfcare unable carry work ) 4 . Normal organ , electrolyte marrow function 1 . Any prior antineoplastic therapy exception patient receive adjuvant imatinib patient newly diagnose metastatic/ unresectable GIST whose disease require therapy await entry study . 2 . Disease progression adjuvant therapy imatinib 3 . History active malignancy ( GIST ) within 10 year prior study entry exception previous concomitant basal cell skin cancer , previous cervical carcinoma situ . 4 . Impaired cardiac function Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Unresectable GIST</keyword>
	<keyword>metastatic GIST</keyword>
	<keyword>nilotinib</keyword>
	<keyword>AMN107</keyword>
	<keyword>imatinib</keyword>
	<keyword>STI571</keyword>
</DOC>